StageZero Life Sciences (TSX:SZLS) EBITDA Margin % : -101.59% (As of Sep. 2023)

View and export this data going back to 2001. Start your Free Trial

What is StageZero Life Sciences EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. StageZero Life Sciences's EBITDA for the three months ended in Sep. 2023 was C$-1.02 Mil. StageZero Life Sciences's Revenue for the three months ended in Sep. 2023 was C$1.01 Mil. Therefore, StageZero Life Sciences's EBITDA margin for the quarter that ended in Sep. 2023 was -101.59%.

StageZero Life Sciences EBITDA Margin % Historical Data

The historical data trend for StageZero Life Sciences's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

StageZero Life Sciences EBITDA Margin % Chart

StageZero Life Sciences Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EBITDA Margin %

Get a 7-Day Free Trial

-1,345.60

-1,814.75

-152.39

-133.67

-283.48

StageZero Life Sciences Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EBITDA Margin %	Get a 7-Day Free Trial															24.30	-1,378.32	-218.95	-30.55	-101.59

Competitive Comparison of StageZero Life Sciences's EBITDA Margin %

For the Diagnostics & Research subindustry, StageZero Life Sciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

StageZero Life Sciences's EBITDA Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, StageZero Life Sciences's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where StageZero Life Sciences's EBITDA Margin % falls into.

StageZero Life Sciences EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

StageZero Life Sciences's EBITDA Margin % for the fiscal year that ended in Dec. 2022 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-14.616	/	5.156
	=	-283.48 %

StageZero Life Sciences's EBITDA Margin % for the quarter that ended in Sep. 2023 is calculated as

EBITDA Margin %	=	EBITDA (Q: Sep. 2023 )	/	Revenue (Q: Sep. 2023 )
	=	-1.024	/	1.008
	=	-101.59 %

StageZero Life Sciences (TSX:SZLS) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

StageZero Life Sciences EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of StageZero Life Sciences's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

StageZero Life Sciences (TSX:SZLS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » StageZero Life Sciences Ltd (TSX:SZLS) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

SZLSF:USA 61N1:Germany

Address

70 East Beaver Creek Road, Unit 30, Richmond Hill, ON, CAN, L4B 3B2

Website

https://www.stagezerolifesciences.com

StageZero Life Sciences Ltd is a vertically integrated healthcare company at the nexus of three sectors of healthcare; Early Cancer Detection, Liquid Biopsy, and Global Telehealth. It is focused on minimizing the risk of cancer and other chronic diseases through early detection and intervention. It continues to develop and commercialize proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a focus on cancer-related indications. It has developed a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. The Company's lead product, Aristotle, is a blood-based molecular diagnostic assessment that can detect an individual's current risk for potentially having a variety of cancers.

StageZero Life Sciences (TSX:SZLS) Headlines

No Headlines